Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 164
Filter
2.
J Fr Ophtalmol ; 44(3): 415-419, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33573797

ABSTRACT

INTRODUCTION: The treatment of conjunctival melanoma is most often conservative, but exenteration is sometimes necessary in order to achieve local control of the disease. It can be performed as a primary procedure in cases of locally advanced disease or as a secondary procedure after one or more recurrences. No benefit to secondary exenteration on patient survival has been demonstrated to date for conjunctival melanoma, and it is generally considered a palliative procedure. PATIENTS AND METHODS: Single-center retrospective study performed in the ocular oncology department of the Institut Curie (Paris, France). We included all patients who underwent secondary orbital exenteration for conjunctival melanoma between January 2008 and January 2016. RESULTS: Twenty-five patients underwent secondary exenteration for conjunctival melanoma. The maximum number of local recurrences prior to exenteration was six. Metastases occurred in 11 patients after exenteration and were more common when there was a greater tumor thickness on histology, if the tumor had not been treated initially in an ocular oncology center, or if there had been a greater number of local recurrences before the secondary exenteration was performed. Seventy-five percent of patients developed metastases when the exenteration was performed after 5 or 6 local recurrences. CONCLUSION: This study suggests that early secondary exenteration (i.e. after a number of local recurrences less than or equal to 4) may reduce the occurrence of metastases (and therefore improve patient survival) in conjunctival melanoma. Thus, secondary exenteration might be a curative surgery in some patients with recurrent disease.


Subject(s)
Conjunctival Neoplasms , Melanoma , Conjunctival Neoplasms/surgery , Humans , Melanoma/surgery , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/surgery , Orbit Evisceration , Retrospective Studies
3.
J Fr Ophtalmol ; 42(10): 1094-1099, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31727330

ABSTRACT

PURPOSE: Our objective was to assess the results of surgical management of palpebral basal cell carcinomas (BCC) followed by a second line treatment discussed during a Multidisciplinary Team Meeting (MTM). MATERIALS AND METHODS: This retrospective single-centred study includes all surgically-treated basal cell carcinomas of the eyelids between January 2005 and January 2015. After initial surgery, the cases were systematically discussed during a multidisciplinary team meeting in order to assess the need for additional treatment. Data relative to the patient, tumor and management were pulled from the medical record. RESULTS: A total of 171 patients were included, with a mean age of 74 years. Among the patients, 151 underwent pentagonal resection of the tumor, and 20 patients had a superficial excision. After surgical management, 120 patients (70.2%) were considered to have sufficient free margins. The other 51 patients (29.8%) had insufficient margins due to remaining tumor cells (38 patients) or free margins less than 1mm. Among these 51 patients with insufficient margins, 19 received a second surgical treatment, 17 patients received adjuvant radiotherapy, and 15 were followed closely with an intensive biannual follow-up program. No patients were lost to follow-up. With a mean follow-up of 42 months (min. 6 months-max. 128 months), 7 out of 171 patients (4.1%) developed a local recurrence. The mean time between surgical management and recurrence was 24 months. The recurrence rate was higher for the group of patients with a recurrent tumor (11.6%) than for the group of patients referred for initial management (2.8%). Incomplete resection was also associated with a higher recurrence rate (3 recurrences out of 51 patients). DISCUSSION: The management of basal cell carcinomas of the eyelid is first and foremost surgical with the goal of complete resection confirmed by histopathological analysis. The histological analyses (Mohs micrographic surgery, frozen section technic, paraffin fixation) and recommended sizes of the margins can vary in the literature, with recurrence rates from 1.8% to 9.5%. CONCLUSION: In our experience, multidisciplinary management of BCC of the eyelid, including initial macroscopic surgery, histopathological analysis stating the histological type and size of the margins, along with additional treatment discussed in a MTM, allows for a recurrence rate of 4.1%.


Subject(s)
Carcinoma, Basal Cell/surgery , Eyelid Neoplasms/surgery , Ophthalmologic Surgical Procedures , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Basal Cell/pathology , Chemotherapy, Adjuvant/statistics & numerical data , Eyelid Neoplasms/epidemiology , Eyelid Neoplasms/pathology , Female , France/epidemiology , Humans , Interdisciplinary Communication , Male , Middle Aged , Neoadjuvant Therapy , Ophthalmologic Surgical Procedures/methods , Ophthalmologic Surgical Procedures/statistics & numerical data , Patient Care Team/organization & administration , Radiotherapy, Adjuvant/statistics & numerical data , Plastic Surgery Procedures/methods , Plastic Surgery Procedures/statistics & numerical data , Retrospective Studies , Treatment Outcome , Young Adult
4.
J Fr Ophtalmol ; 41(5): 412-420, 2018 May.
Article in English | MEDLINE | ID: mdl-29778279

ABSTRACT

INTRODUCTION: Surgical excision of large malignant lower eyelid tumors may cause important full-thickness eyelid defects. The reconstruction of such defects must restore the physiologic function of the eyelid and also re-establish an acceptable aesthetic result. MATERIALS AND METHODS: We report the outcomes of full-thickness excision of tumors extending over half of the horizontal lid length, followed by reconstruction using a nasal chondromucosal graft (coming from the ipsilateral ala of the nose) and an upper eyelid myocutaneous flap. Histological analysis of the specimen identified the tumor type and surgical margins for each patient. RESULTS: A total of 25 patients were operated using this reconstruction technique between March 2009 and June 2015: 17 basal cell carcinomas, 3 spindle cell carcinomas and 5 conjunctival melanomas (out of which 2 were associated with lentigo maligna). Mean duration of follow-up after surgery was respectively 36, 41 and 17 months for each of these 3 tumor types. We found a single local tumor recurrence and this was a basal cell carcinoma in a xeroderma pigmentosum patient. After surgery, none of the patients had lagophthalmos or ocular surface complications. Only 4 patients had a 1mm scleral show postoperatively; 3 other patients developed a small retraction of the eyelid after adjuvant radiotherapy and a 1mm scleral show occurred. CONCLUSION: In malignant tumors, complete surgical excision with histological margins adapted to tumor type prevents local recurrence in most cases. Our repair strategy of nasal chondromucosal graft and skin-muscle flap for large inferior eyelid defects provides good functional and aesthetic results.


Subject(s)
Blepharoplasty/methods , Carcinoma, Basal Cell/surgery , Eyelid Neoplasms/surgery , Myocutaneous Flap/transplantation , Nasal Cartilages/transplantation , Respiratory Mucosa/transplantation , Adult , Aged , Aged, 80 and over , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Eyelid Neoplasms/pathology , Female , Humans , Male , Melanoma/pathology , Melanoma/surgery , Middle Aged , Nasal Cartilages/surgery , Nose/pathology , Nose/surgery , Plastic Surgery Procedures/methods , Respiratory Mucosa/surgery , Retrospective Studies , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Skin Transplantation/methods , Treatment Outcome , Young Adult
5.
J Fr Ophtalmol ; 40(2): 93-101, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28126270

ABSTRACT

PURPOSE: Evisceration can be performed for blind, painful eyes. This surgery can promote the dissemination of tumor cells within the orbit if an ocular tumor has been missed preoperatively. METHODS: We reviewed the medical records of patients who were eviscerated for blind, painful eyes between 2009 and 2014 and who were referred after the surgery to the Institut Curie or the Rothschild Foundation in Paris. We included the patients with a histological diagnosis of ocular tumor or orbital recurrence. Cytogenetic analysis was performed whenever possible. RESULTS: Four patients turned out to have an ocular tumor after evisceration (two choroidal melanomas, a rhabdoid tumor and an adenocarcinoma of the retinal pigment epithelium); two had a history of prior ocular trauma. The tumors were diagnosed either on histological analysis of the intraocular contents (2 patients) or biopsy of orbital recurrence (2 patients). Prior to evisceration, fundus examination was not performed in 3 patients. One had preoperative imaging but no intraocular tumor was suspected. At the time of this study, 3 patients had had an orbital recurrence and died. We also found 2 patients who had an evisceration despite a past history of choroidal melanoma treated with proton beam therapy. CONCLUSION: We showed that evisceration of eyes with unsuspected ocular malignancies was associated with a poor prognosis due to orbital recurrence and metastasis. The evisceration specimen should therefore always be sent for histological analysis in order to perform prompt adjuvant orbital radiotherapy if an ocular tumor is found.


Subject(s)
Adenocarcinoma/pathology , Adenocarcinoma/surgery , Eye Evisceration , Eye Neoplasms/pathology , Eye Neoplasms/surgery , Adult , Aged, 80 and over , Choroid Neoplasms/pathology , Choroid Neoplasms/surgery , Eye Enucleation , Female , Humans , Male , Melanoma/pathology , Melanoma/surgery , Middle Aged , Neoplasm Recurrence, Local , Retrospective Studies , Uveal Neoplasms/pathology , Uveal Neoplasms/surgery
6.
J Fr Ophtalmol ; 39(5): 467-73, 2016 May.
Article in French | MEDLINE | ID: mdl-27157036

ABSTRACT

PURPOSE: To describe the epidemiological and clinical parameters of conjunctival squamous cell carcinomas and their association with HIV-AIDS in the ophthalmology department of the university hospital of Treichville. PATIENTS ET METHODS: This is a prospective and descriptive cross sectional study carried out in the ophthalmology department of the university hospital of Treichville from July 2007 to June 2011. Twenty-six (26) patients who were selected presented with a tumor of the globe and/or adnexa. A CT scan was performed in advanced cases. Histopathological examination of the surgical specimen was performed in all cases. HIV serology was performed after informed consent. All patients were referred to the oncology department of the university hospital of Treichville where a unit of care for HIV-positive patients with malignant tumors is available. Statistical analysis was performed using the software program EPI info version 6.0. RESULTS: We note a slight predominance of female patients 15 (57.69%) vs. 11 (42.3%) male patients. The mean age was 42.32 years, and 13 patients (50%) were between 25 and 45 years of age. Intraorbital tumors were the most common reason for consultation, i.e. 38.46%. Seventeen patients (65.38%) had no particular history. Nine patients (34.61%) were already on antiretroviral treatment on admission. Three patients, i.e. 11.54%, had already had tumor biopsy and/or evisceration. The mean duration of the disease before consultation in ophthalmology was 14.28 months. Localized limbal conjunctival tumors were found in 11 cases (42.38%). Advanced tumors with regional or cerebral extension accounted for 34.61% of cases. Six patients (23.078%) were HIV negative vs. 20 (76.92%) HIV positive patients. CD4 lymphocyte typing was performed in 17 patients (85%), and 45% had a CD4 count below 200. Only five patients were able to receive neoadjuvant chemotherapy, but three of them died. The average length of follow-up was 29 months. COMMENT: This study allowed us to establish a statistically significant link between HIV positive status of patients and the occurrence of squamous cell carcinoma, (P=10(-4)), as well as the decline in CD4 count and disease progression (p=10(-3)). CONCLUSION: The poor prognosis of conjunctival carcinoma reflects the low socioeconomic status of patients, physician under-staffing in our health care facilities, the prohibitive cost of anticancer drugs and the link between this disease and HIV-AIDS.


Subject(s)
Acquired Immunodeficiency Syndrome/epidemiology , Carcinoma, Squamous Cell/epidemiology , Conjunctival Neoplasms/epidemiology , HIV Infections/epidemiology , Acquired Immunodeficiency Syndrome/complications , Adult , Carcinoma, Squamous Cell/complications , Conjunctival Neoplasms/complications , Cote d'Ivoire/epidemiology , Cross-Sectional Studies , Female , HIV Infections/complications , HIV-1 , Hospitals, University , Humans , Male , Middle Aged
7.
Eye (Lond) ; 30(1): 46-52, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26427984

ABSTRACT

PurposeIntraocular retinoblastoma treatments often combine chemotherapy and focal treatments. A first prospective protocol of conservative treatments in our institution showed the efficacy of the use of two courses of chemoreduction with etoposide and carboplatin, followed by chemothermotherapy using carboplatin as a single agent and diode laser. In order to decrease the possible long-term toxicity of chemotherapy due to etoposide, a randomized neoadjuvant phase II protocol was conducted using vincristine-carboplatin vs etoposide-carboplatin.Patients and methodsThe study was proposed when initial tumor characteristics did not allow front-line local treatments. Patients included in this phase II noncomparative randomized study of neoadjuvant chemotherapy received vincristin-carboplatin (new arm) vs etoposide-carboplatin (our reference arm). They were subsequently treated by local treatments and chemothermotherapy. Primary end point was the need for secondary enucleation or external beam radiotherapy (EBRT) not exceeding 40% at 2 years.ResultsA total of 65 eyes in 55 children were included in the study (May 2004 to August 2009). Of these, 32 eyes (27 children) were treated in the arm etoposide-carboplatin and 33 eyes (28 children) in the arm vincristin-carboplatin. At 2 years after treatment, 23/33 (69.7%) eyes were treated and salvaged without EBRT or enucleation in the arm vincristin-carboplatin and 26/32 (81.2%) in the arm etoposide-carboplatin.ConclusionEven if the two treatment arms could be considered as sufficiently active according to the study decision rules, neoadjuvant chemotherapy by two cycles of vincristine-carboplatin followed by chemothermotherapy appear to offer less optimal local control than the etoposide-carboplatin combination.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hyperthermia, Induced , Neoadjuvant Therapy , Retinal Neoplasms/therapy , Retinoblastoma/therapy , Carboplatin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Infant , Male , Prospective Studies , Retinal Neoplasms/classification , Retinal Neoplasms/pathology , Retinoblastoma/classification , Retinoblastoma/pathology , Vincristine/administration & dosage
9.
J Fr Ophtalmol ; 38(6): 514-5, 2015 Jun.
Article in French | MEDLINE | ID: mdl-26046832
10.
J Fr Ophtalmol ; 38(6): 526-34, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25978872

ABSTRACT

Despite advances in the local treatment of UM, half of patients develop metastases typically to the liver with poor survival. Microscopic complete surgical resection (R0) of liver metastases improves survival in high selected patients. Early identification of high-risk patients might allow detection of asymptomatic metastases, and increase R0 liver surgery rate. From October 2006 to December 2009, we conducted a prospective study to detect early minimal lesions with 6-monthly liver function tests (LFTs) and liver MRI in 100 high-risk patients. High risk was defined by primary tumor clinical or genomic criteria: thickness>8mm or diameter>15 mm, or extra-scleral extension, or monosomy 3 by FISH or aCGH. With a median follow-up of 49 months, the 5-year metastasis-free survival and overall survival were 47 and 33%, respectively. Of the 60 patients who became metastatic, 50 (83%) had exclusive liver metastasis. LFTs screening had no sufficient accurary, but biannual MRI showed high predictive value to detect metastasis and select patients eligible for curative surgery: 25/50 underwent laparotomy and among them, 8/25 (32%) had a R0 surgery. Median survival after metastasis was 14 months, mean survival reached 40 months in the R0 resected population. Six-monthly liver MRI screening is recommended in patients with large tumors or genomic high risk in order to detect early patient candidates to complete resection of liver metastases.


Subject(s)
Early Diagnosis , Liver Neoplasms/diagnosis , Liver Neoplasms/secondary , Melanoma/diagnosis , Melanoma/secondary , Uveal Neoplasms/diagnosis , Uveal Neoplasms/secondary , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Disease-Free Survival , Early Medical Intervention , Female , Genetic Predisposition to Disease/genetics , Humans , Liver Function Tests , Liver Neoplasms/mortality , Liver Neoplasms/surgery , Magnetic Resonance Imaging , Male , Melanoma/genetics , Melanoma/mortality , Melanoma/surgery , Metastasectomy/methods , Microsurgery/methods , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Uveal Neoplasms/genetics , Uveal Neoplasms/mortality , Uveal Neoplasms/surgery , Young Adult
11.
J Fr Ophtalmol ; 38(6): 535-41, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25976136

ABSTRACT

INTRODUCTION: To describe the results of retinoblastoma treatment from 1995-2009 in a single institution. MATERIAL AND METHODS: Retrospective review of the charts of patients treated for retinoblastoma. Clinical characteristics at diagnosis, treatments and outcomes in terms of survival and ocular preservation are described. RESULTS: During the study period 826 children were referred for retinoblastoma and 730 were managed in our institution. Four hundred and eleven children presented with unilateral retinoblastoma and 319 with bilateral retinoblastoma. Median follow-up is of 93 months. Global survival is 98.5% of children, 10 children presented with second tumors, 11 children died (6 of tumor-related causes). Of the 411 children with unilateral retinoblastoma enucleation was needed at diagnosis for 324 (78.8%). Conservative treatments were attempted for 87 patients (21.2%) and ocular preservation obtained for 65 patients (74% of eyes). Three hundred and nineteen patients presented with bilateral retinoblastoma. Three hundred and ten could be treated conservatively for at least one eye. Initial intravenous chemotherapy was necessary for 75% of them. Ocular preservation without external beam radiation was possible for 221 patients (70%). The use of EBR decreased significantly after 2004 (9.1% of eyes vs 25.1%: P<0.001). DISCUSSION: Management and treatment of retinoblastoma are complex, adapted to the extent of the disease. Survival is good. Enucleation is still required for extensive ocular disease, especially for unilateral patients. Intravenous chemotherapy allows good tumor control and eye preservation and decrease the need of EBR. CONCLUSIONS: Retinoblastoma treatment with intravenous chemotherapy and ocular adjuvant therapies is very effective on the local tumor control and eye preservation.


Subject(s)
Neoplasms, Multiple Primary/therapy , Retinal Neoplasms/therapy , Retinoblastoma/therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemotherapy, Adjuvant , Child , Child, Preschool , Combined Modality Therapy , Eye Enucleation , Female , Follow-Up Studies , Genetic Predisposition to Disease , Humans , Hyperthermia, Induced , Infant , Infant, Newborn , Infusions, Intravenous , Male , Neoplasms, Multiple Primary/mortality , Neoplasms, Multiple Primary/pathology , Organ Preservation , Radiotherapy/methods , Retinal Neoplasms/genetics , Retinal Neoplasms/mortality , Retinal Neoplasms/pathology , Retinoblastoma/genetics , Retinoblastoma/mortality , Retinoblastoma/pathology , Retrospective Studies , Survival Analysis
12.
Ann Dermatol Venereol ; 142(1): 26-36, 2015 Jan.
Article in French | MEDLINE | ID: mdl-25600792

ABSTRACT

Cutaneous melanoma is a multifactorial disease resulting from both environmental and genetic factors. Five susceptibility genes have been identified over the past years, comprising high-risk susceptibility genes (CDKN2A, CDK4, and BAP1 genes) and intermediate-risk susceptibility genes (MITF, and MC1R genes). The aim of this expert consensus was to define clinical contexts justifying genetic analyses, to describe the conduct of these analyses, and to propose surveillance recommendations. Given the regulatory constraints, it is recommended that dermatologists work in tandem with a geneticist. Genetic analysis may be prescribed when at least two episodes of histologically proven invasive cutaneous melanoma have been diagnosed before the age of 75 years in two 1st or 2nd degree relatives or in the same individual. The occurrence in the same individual or in a relative of invasive cutaneous melanoma with ocular melanoma, pancreatic cancer, renal cancer, mesothelioma or a central nervous system tumour are also indications for genetic testing. Management is based upon properly managed photoprotection and dermatological monitoring according to genetic status. Finally, depending on the mutated gene and the familial history, associated tumour risks require specific management (e.g. ocular melanoma, pancreatic cancer). Due to the rapid progress in genetics, these recommendations will need to be updated regularly.


Subject(s)
Genetic Predisposition to Disease , Genetic Testing , Melanoma/genetics , Skin Neoplasms/genetics , Cyclin-Dependent Kinase 4/genetics , Cyclin-Dependent Kinase Inhibitor p16/genetics , Genotype , Humans , Microphthalmia-Associated Transcription Factor/genetics , Mutation , Receptor, Melanocortin, Type 1/genetics , Tumor Suppressor Proteins/genetics , Ubiquitin Thiolesterase/genetics
14.
J Fr Ophtalmol ; 37(2): 99-106, 2014 Feb.
Article in French | MEDLINE | ID: mdl-24210936

ABSTRACT

PURPOSE: Retrospective study of local tolerability of a natural hydroxyapatite orbital implant wrapped with Vicryl(®) (polyglactin) mesh in patients undergoing enucleation. METHOD: Complications were classified into four types according to their management: type 1 if no reoperation was required, type 2 if additional surgery without grafting was required, type 3 if an oral mucosal graft was performed (major dehiscence) and type 4 if the complication required removal of the implant. RESULTS: Seven hundred and four patients with a median follow-up of 44 months. Five hundred and three patients were enucleated as a primary procedure and 201 after failure of conservative management. The overall complication rate was 12.07% (85 patients) with 68 type 1 complications, nine type 2 complications, three type 3 complications and five type 4 complications (0.71%). A total of 17 patients (2.42%) required additional surgery. The use of chemotherapy or radiotherapy before or after surgery did not influence the results. In univariate analysis, the tolerability was better in children than in adults. With multivariate analysis, only the diameter of the implant was an independent risk factor for complications (P=0.001). CONCLUSION: Use of a Vicryl(®) mesh-wrapped natural hydroxyapatite orbital implant after enucleation is particularly well tolerated including the pediatric population. A compromise should be sought with an implant large enough for good cosmetic results but small enough to avoid complications.


Subject(s)
Durapatite/chemistry , Eye Enucleation , Orbital Implants , Polyglactin 910/chemistry , Adolescent , Adult , Child , Child, Preschool , Durapatite/adverse effects , Eye Enucleation/statistics & numerical data , Eye Neoplasms/epidemiology , Eye Neoplasms/surgery , Female , Humans , Infant , Male , Middle Aged , Orbital Implants/adverse effects , Polyglactin 910/adverse effects , Postoperative Complications/epidemiology , Prosthesis Implantation/adverse effects , Reoperation/statistics & numerical data , Retrospective Studies , Surgical Mesh/adverse effects , Surgical Wound Dehiscence/epidemiology , Surgical Wound Dehiscence/etiology
15.
Eye (Lond) ; 27(7): 828-35, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23598677

ABSTRACT

PURPOSE: To describe the clinical and imaging presentation, pitfalls in the diagnosis of choroidal extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), as well as the therapeutic management and prognosis. METHODS: A retrospective case review of nine choroidal MALT lymphomas was performed. Initial clinical presentation and imaging findings of these histologically confirmed cases of lymphoma were analyzed. Treatment methods, time to diagnosis, systemic work-up, and treatment prognosis were assessed. RESULTS: Initial presentation was essentially blurred vision. The features described on examination were: anterior and posterior scleritis, iridocyclitis, choroidal infiltration, and exudative retinal detachment. Fluorescein and indocyanine green angiography as well as ultrasonography and optic coherence tomography provided arguments in favor of the diagnosis. Biopsy sites included conjunctiva, Tenon's capsule, deep scleral tissue, episclera, lacrimal gland, and choroid. Treatment mostly consisted of a combination of chemotherapy and radiotherapy. The mean time to diagnosis was 12 months. CONCLUSIONS: Owing to the insidious onset of these tumors and their ability to simulate other conditions, the diagnosis is commonly delayed. The prognosis is generally good and treatment is effective in the case of localized lymphoma.


Subject(s)
Choroid Neoplasms/diagnosis , Lymphoma, B-Cell, Marginal Zone/diagnosis , Adult , Aged , Antineoplastic Agents/therapeutic use , Choroid Neoplasms/therapy , Early Diagnosis , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Lymphoma, B-Cell, Marginal Zone/therapy , Male , Middle Aged , Retrospective Studies , Tomography, Optical Coherence
16.
J Fr Ophtalmol ; 36(5): 431-4, 2013 May.
Article in English | MEDLINE | ID: mdl-23306179

ABSTRACT

We report a case of primary intraocular central nervous system (CNS) lymphoma in a patient previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections for age-related macular degeneration (AMD). An 88-year-old woman, with past medical history significant for bilateral age-related macular degeneration (AMD) treated with intravitreal ranibizumab injections for 1 year, was referred to our department for bilateral vitritis diagnosed 10 days after the last anti-VEGF injection. A complete uveitis work-up including aqueous humour analysis, brain MRI and vitreous biopsy enabled us to confirm the diagnosis of primary intraocular CNS lymphoma. To the best of our knowledge, this is the first report of the diagnosis of primary intraocular CNS lymphoma in a patient treated with anti-VEGF for AMD. The differential diagnosis of vitritis in elderly patients is relatively broad. Endophthalmitis and uveitis have been described after anti-VEGF injections. In such a situation, there is actually a risk of missing the diagnosis of intraocular lymphoma in the mistaken belief that the observed vitritis may be a reaction to administered anti-VEGFs. If no direct time-relationship with the anti-VEGF injections can be found, a classic vitritis work-up should be performed. Our observation suggests that ranibizumab, at the dosage used for AMD, does not impede the spread of CNS lymphoma in the eye nor interfere with cytological diagnosis.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Eye Neoplasms/diagnosis , Lymphoma/diagnosis , Macular Degeneration/drug therapy , Aged, 80 and over , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Central Nervous System Neoplasms/complications , Central Nervous System Neoplasms/diagnosis , Diagnosis, Differential , Endophthalmitis/chemically induced , Endophthalmitis/diagnosis , Eye Neoplasms/complications , Female , Humans , Intravitreal Injections , Lymphoma/complications , Macular Degeneration/complications , Ranibizumab , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/immunology
18.
J Fr Ophtalmol ; 35(6): 420-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22633214

ABSTRACT

BACKGROUND: Uveal metastases (UM) are the most common intraocular malignancies and can be the first manifestation of a disseminated disease. The purpose of this study is to determine the frequency with which uveal metastasis results in a diagnosis of lung cancer, to describe the clinical characteristics of patients with lung cancer metastatic to the uvea, as well as diagnostic difficulties that may be encountered. PATIENTS AND METHODS: We carried out a single-center retrospective study of the medical records of all patients who presented with a UM between 1999 and 2010 at the institut Curie in Paris. From these patients, we retrospectively studied UM secondary to lung cancer. A work-up including thoracic-abdominal-pelvic CT was performed for each patient in whom the primary source of choroidal metastasis was unknown. RESULTS: Of 109 patients presenting with UM, 43 were diagnosed with primary lung cancer (39.4%). Of those 43 patients, the UM was observed prior to the lung cancer in 31 patients (72.1%). Demographic data included 61% male and 39% female, mean age 59.1 years (range: 31-78), and mean life expectancy after diagnosis of UM was 7.5 months (range: 0.7-29). Other metastatic sites were associated with UM in 90.7% of the patients. In all, 90.7% of the patients presented with blurred vision, and 25.6% with pain or inflammation. UM were located within the choroid for 39 patients (90.7%), the iris for three patients (7.3%) and the vitreous for one patient. Seventy percent of patients had a solitary lesion, 76.7% had unilateral involvement, and 23.3% of cases were bilateral. Mean thickness on B-scan ultrasonography was 3.61 mm (range: 1-8.5 mm). In all, 81.4% of UM were unpigmented, while 18.6% showed pigment mottling. In all, 20.9% of patients were referred with the diagnosis of choroidal melanoma from their regular ophthalmologist, and three of the 43 patients (6.9%) were initially misdiagnosed and treated for melanoma at Curie. Chest X-ray was unremarkable in 18.9% of patients. CONCLUSION: UM is often the first manifestation of disseminated disease and requires a search for the primary tumor, in particular lung cancer. Standard chest X-ray cannot rule out the diagnosis. Metastases may be solitary with heterogenous pigmentation, and the differential diagnosis from uveal melanoma may be difficult, requiring the expertise of a referral center.


Subject(s)
Carcinoma/diagnosis , Carcinoma/pathology , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Uveal Neoplasms/diagnosis , Uveal Neoplasms/secondary , Adult , Aged , Carcinoma/epidemiology , Diagnosis, Differential , Diagnostic Errors/statistics & numerical data , Female , Humans , Lung Neoplasms/epidemiology , Male , Middle Aged , Neoplasms, Unknown Primary/diagnosis , Neoplasms, Unknown Primary/epidemiology , Radiography, Thoracic , Retrospective Studies , Uveal Neoplasms/epidemiology
19.
Osteoporos Int ; 23(7): 2017-25, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22109743

ABSTRACT

SUMMARY: The hormone fibroblast growth factor 23 (FGF23) is involved in mineral homeostasis but may also have a role in vascular calcification and bone mineralization. In a cohort of 142 patients with CKD stages 2-5D, plasma FGF23 was independently associated with aortic calcification but not with pulse wave velocity or bone mineral density. INTRODUCTION: FGF23 is involved in mineral homeostasis but may also have a role in vascular calcification and bone mineralization. Previous studies related to FGF23 and vascular and bone outcomes have been restricted to dialysis patients. The aim of the present study was to establish whether or not plasma FGF23 is associated with aortic and coronary calcification, arterial stiffness, and bone mineral density in patients with early as well as late stages of CKD. METHODS: In a cohort of 142 patients with CKD stages 2-5D, we made routine biochemistry and intact FGF23 determinations, and assessed aortic and coronary calcification, bone mineral density (BMD), and arterial stiffness by multislice spiral computed tomography and automated pulse wave velocity (PWV). RESULTS: Plasma intact FGF23 levels were elevated in CKD patients; the elevation preceded that of serum phosphate in early-stage CKD. Patients with elevated FGF23 levels had higher aortic and coronary calcification scores than patients with lower FGF23 levels. Multivariate linear regression analysis indicated that only age (p < 0.001) and FGF23 (p = 0.008) were independently associated with aortic calcification score. Plasma FGF23 was neither associated with PWV nor with BMD. CONCLUSION: Our data suggest that plasma FGF23 is an independent biomarker of vascular calcification in patients with various CKD stages including early stages. The association between vascular calcification and FGF23 levels appears to be independent of BMD. It remains to be seen whether this association is independent of bone turnover and bone mass.


Subject(s)
Bone Density/physiology , Fibroblast Growth Factors/physiology , Kidney Failure, Chronic/blood , Vascular Calcification/blood , Aged , Aortic Diseases/blood , Aortic Diseases/etiology , Biomarkers/blood , Blood Flow Velocity/physiology , Cohort Studies , Coronary Disease/blood , Coronary Disease/etiology , Female , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Glomerular Filtration Rate/physiology , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/physiopathology , Male , Middle Aged , Multidetector Computed Tomography/methods , Pulsatile Flow/physiology , Severity of Illness Index , Vascular Calcification/etiology , Vascular Stiffness/physiology
20.
Eye (Lond) ; 25(12): 1555-61, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21921957

ABSTRACT

AIMS: To assess if systematic fundus screening according to an 'intensive' schedule alters ocular outcome and to propose fundus screening schedule guidelines for children related to a retinoblastoma patient. METHODS: For children with a positive family history of retinoblastoma, we perform fundus exams shortly after birth under general anaesthesia and then at regular intervals according to schedules based on the risk. Familial retinoblastoma cases seen at our institution from January 1995 to December 2004 were retrospectively classified as 'screened' or 'non-screened' (NS) and, among the 'screened' patients, as 'intensively screened' (IS) if screening matched our recommendations or 'non-intensively screened' (S). Groups were compared by Fisher exact test for categorical variables and Kruskal-Wallis test for continuous variables. RESULTS: Among the 547 retinoblastoma patients managed at our institution during this period, 59 were familial cases. In all, 20 were in the NS group, 23 in the S group, and 16 in the IS group. The number of children enucleated was, respectively, 13, 2, and 0 (P<10(-4)); external beam radiation (EBRT) was required for, respectively, 6, 0, and 2 children (P<0.009). Chemotherapy burden and visual acuity were not significantly different between groups. CONCLUSION: An 'intensive' fundus screening schedule decreased the need for enucleation and EBRT. Therefore, despite the heavy burden of the screening schedule, we recommend physicians and health-care professionals to better inform and refer children with a family history of retinoblastoma for genetic counselling and proper fundus screening in specialized centres.


Subject(s)
Fundus Oculi , Mass Screening/methods , Practice Guidelines as Topic , Retinal Neoplasms/diagnosis , Retinoblastoma/diagnosis , Adolescent , Child , Child, Preschool , Eye Enucleation/statistics & numerical data , Female , Humans , Infant , Male , Neoplasm Staging , Retinal Neoplasms/genetics , Retinal Neoplasms/pathology , Retinal Neoplasms/therapy , Retinoblastoma/genetics , Retinoblastoma/pathology , Retinoblastoma/therapy , Retrospective Studies , Statistics, Nonparametric , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...